Avidex and Anosys complete successful collaboration in CANCER vaccine development
UK biotech firm Avidex and US biotech firm Anosys announce the successful completion of a collaboration using Avidex's soluble T cell receptors to validate T cell antigen Expression on Anosys' Dexosome cancer vaccines.
Anosys' Dexosomes use small vesicles derived from immune cells that contain all the necessary components to trigger the major immune responses required to fight diseases. Avidex's mTCRs are soluble antigen specific proteins which specifically recognise and bind T cell antigens on the surface of cells with high affinity and specificity.
This is the first time the levels of antigen expression on a vaccine particle have been measured directly and is a landmark in the direct validation and quantification of HLA/peptide vaccine antigens. Moreover, this confirms T cell antigens are expressed at high levels in Anosys's vaccine and is a significant step in validating T cell antigen expression in therapeutic vaccine development.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
